Loading stock data…
$1.13+0.09 (+8.17%)
biote Corp.
biote Corp. in the Healthcare sector is trading at $1.12 with a market capitalization of $38M. Wall Street consensus targets $2.61 (5 analysts), implying a +132.2% move over the next 12 months. The stock is currently near its 52-week low of $1.00, remaining 41.1% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.23M↓ | $44.94M↓ | $46.41M↓ | $47.96M↓ | $48.86M |
| Gross Profit | $28.92M↓ | $30.95M↓ | $31.57M↓ | $34.42M↓ | $34.99M |
| Operating Income | -$3.51M↓ | $3.17M↓ | $6.83M↓ | $8.27M↓ | $10.77M |
| Net Income | -$6.56M↓ | $2.28M↑ | $1.95M↓ | $8.19M↑ | $3.19M |
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormona...